Rubraca Archives -

Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP

Clovis steals march on AZ with PARP prostate approval

https://pharmaphorum.com/news/clovis-steals-march-on-az-with-parp-prostate-approval/

NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to

New price gets Clovis’ PARP inhibitor on the CDF

https://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/

GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer

https://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/

European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage

Janssen CAR-T is Priority Medicine in EU, and more

https://pharmaphorum.com/views-analysis-oncology/janssen-car-t-is-priority-medicine-in-eu-and-more/

Shares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it.

Tesaro stock rockets as rumours of Roche takeover abound

https://pharmaphorum.com/news/tesaro-stock-rockets-roche-takeover-abound/

Rubraca